慢性肝病与肝硬化的当代流行病学
美国肝硬化患病率和死亡率近年上升,病因谱正随乙肝疫苗接种、丙肝治疗、代谢综合征和酒精滥用变化而转变。
要点
- 美国肝硬化患病率和死亡率近年上升。
- 慢性肝病流行病学正随乙肝疫苗、丙肝治疗、代谢综合征和酒精滥用而变化。
核心结论
- 全球慢性肝病和肝硬化负担沉重;乙肝和丙肝的疫苗、筛查及抗病毒治疗降低了部分地区的负担,但注射吸毒、酒精滥用和代谢综合征的增加威胁这些趋势。
研究设计与样本
- 综述已发表的关于慢性肝病各病因及并发症(包括肝硬化和肝细胞癌)的发病率、患病率和趋势的文献。
- 补充美国疾病控制中心和全球疾病负担研究中关于慢性肝病、肝硬化和肝细胞癌的发病和死亡更新数据。
- 评估现有数据来源的优势与局限,为肝硬化负担的国家估计提供背景。
主要发现
- 慢性肝病和肝硬化的年龄标化发病率为20.7/100,000,自2000年以来增加13%。
- 美国近年肝硬化患病率和死亡率上升。
- 慢性肝病流行病学正在转变,反映乙肝疫苗接种和丙肝治疗项目的实施、代谢综合征患病率增加以及酒精滥用增加。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Accurate estimates for the contemporary burden of chronic liver disease (CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the incidence, prevalence, and mortality of CLD and its resulting complications, including cirrhosis and hepatocellular carcinoma (HCC). METHODS: We reviewed the published literature on the incidence, prevalence, trends of various etiologies of CLD and its resulting complications. In addition, we provided updated data from the Centers for Disease Control and Global Burden of Disease Study on the morbidity and mortality of CLD, cirrhosis, and hepatocellular carcinoma (HCC). Lastly, we assessed the strengths and weaknesses of available sources of data in hopes of providing important context to these national estimates of cirrhosis burden. RESULTS: An estimated 1.5 billion persons have CLD worldwide and the age-standardized incidence of CLD and cirrhosis is 20.7/100,000, a 13% increase since 2000. Similarly, cirrhosis prevalence and mortality has increased in recent years in the United States. The epidemiology of CLD is shifting, reflecting implementation of large-scale hepatitis B vaccination and hepatitis C treatment programs, the increasing prevalence of the metabolic syndrome, and increasing alcohol misuse. CONCLUSIONS: The global burden of CLD and cirrhosis is substantial. Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the CLD burden in some parts of the world, concomitant increases in injection drug use, alcohol misuse, and metabolic syndrome threaten these trends. Ongoing efforts to address CLD-related morbidity and mortality require accurate contemporary estimates of epidemiology and outcomes.
引用
- Moon AM, Singal AG, Tapper EB, et al. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2019. PMID: 31401364. doi:10.1016/j.cgh.2019.07.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。